Summary

The global Tubeless Insulin Pumps market size was valued at $2.65 billion in 2026, and is projected to reach $7.19 billion by 2032, growing at a CAGR of 18.1% during the forecast period.

? A tubeless insulin pump is a device for administering insulin for diabetes patients of all ages. Diabetic patients are highly preferring tubeless device as it has given them reliable, 24 hour, and continuous supply of insulin, these pumps do not use rubber gloves and they are visually more unobtrusive than traditional systems because they do not require periodic cleaning and re-oiling, which can lead to infection. In addition, the increasing diabetes patients across the globe will further increase the adoption of tubeless insulin pumps, according to the World Health Organization (WHO), around 1.6 million deaths occurred in 2016, due to diabetes. This factor is expected to augment the industry growth in foreseeable future.

? Additionally, technological advancements, and rising government initiatives to raise awareness about diabetes management worldwide are the prominent factors anticipated to boost the tubeless insulin pumps market growth in the forecast period.

? However, high cost of the tubeless insulin pumps and hostile reimbursement policies are expected to obstruct the market growth.

Insulin pumps are small, computerized devices designed and programmed to deliver prearranged doses of insulin into a diabetic person. Tubeless pumps typically use a pressurized reservoir that is protected by an outer casing with a porous membrane that can be penetrated with the needle of an infusion set. Increased adoption of non-invasive transdermal insulin delivery systems has improved the patient compliance for diabetes treatment. Usage of micro-emulsion sand micro needles improves permeation of insulin through the transdermal route. Other effective routes of insulin administration such as oral, buccal, nasal and others is explored as alternative non-invasive modes of delivery.

By Component, the Pod/Patch Segment to Experience Dynamic Growth through 2026

The Pod/patch segment is estimated to have a lucrative growth in the forecast period owing to rising adoption of pod/patch for convenient handling and easy administration of insulin at appropriate time intervals. Pod/patch is enabled with insulin reservoirs and insulin insertion set for topical distribution. Emerging firms are innovating such insulin delivery devices with advancements such as Bluetooth-enabled devices, wearables, closed-loop systems among others. Improvement in pod’s size and functions will fuel the tubeless insulin pump demand over the coming years.

By Geography, North America is Leading in the Global Market Place

The demand is mainly due to the lack of physical activity and rising old age population among the people in this region can be the biggest region for the increase in the diabetic population. U.S. and Canada are expected to witness a significant growth in the diabetic population over the coming years. According to Canada Statistics, around 2.3 million Canadians, aged 12 years and above were diagnosed with diabetes in 2017. In addition, new product launch and continuous upgradation in technology will lead the region to greater demand over the forthcoming years.

List of the Key Players Profiled in the Market Include:

? Insulet Corporation
? Medtrum Technologies Inc
? Debiotic
? Roche Holding AG
? Spring Health Solution Ltd
? Cellnovo Group SA
? Johnson & Johnson
? Abbott Diabetes Care
? Medtronic Plc
? CeQur SA
? Veleritas
? Tandem Diabetes Care
? Animas Corporation

What Can be Explored with this Research Report:

? Understand the key trends that will drive the market, challenges it faces in the current market scenario.
? Identify growth opportunities.
? Porter’s five force analysis.
? In-depth analysis of market segments, and regions/countries predicted to observed promising growth.
? Historical and forecast size of the market in terms of revenue (USD Million).
? Company profiling with key products and solution offerings, key financial information, SWOT analysis, and business strategies adopted.

Market Segmentation:

The research report includes in-depth coverage of the industry analysis with size, share, and forecast for the below segments:

Market by, Component:
? Pod/patch
? Remote
? Accessories (Reservoirs, Batteries)

Market by, Distribution Channel:
? E-commerce
? Hospitals
? Pharmacies

Market by, Geography:
? North America
? Europe
? Asia Pacific
? South America
? Middle East & Africa

ページTOPに戻る

Table of Contents

1 Market Overview
1.1 Introduction
1.2 Research Objectives
1.3 Market Segmentation
1.4 Stakeholders
1.5 List of Acronyms

2 Executive Summary

3 Research Methodology
3.1 Identification of Data
3.2 Evaluation of Market Dynamics
3.3 Collaboration of Data
3.4 Verification and Analysis
3.5 Data Sources
3.6 Assumptions

4 Market Dynamics
4.1 Market Drivers
4.1.1 Increasing prevalence of diabetes worldwide
4.1.2 Rise in technological advancements
4.2 Market Restraints
4.2.1 High cost of the tubeless insulin pumps
4.3 Market Opportunities
4.3.1 Increasing government initiatives and rising awareness about diabetes
4.4 Market Challanges
4.4.1 Presence of alternative devices
4.5 Impact of COVID-19 on Tubeless Insulin Pumps Market

5 Porter's Five Force Analysis
5.1 Bargaining Power of Suppliers
5.2 Bargaining Power of Buyers
5.3 Threat of New Entrants
5.4 Threat of Substitutes
5.5 Competitive Rivalry in the Market

6 Global Tubeless Insulin Pumps Market by, Component
6.1 Overview
6.2 Pod/patch
6.3 Remote
6.4 Accessories (Reservoirs, Batteries)

7 Global Tubeless Insulin Pumps Market by, Distribution Channel
7.1 Overview
7.2 E-commerce
7.3 Hospitals
7.4 Pharmacies

8 Global Tubeless Insulin Pumps Market by, Geography
8.1 Overview
8.2 North America
8.3 Europe
8.4 Asia Pacific
8.5 South America
8.6 Middle East & Africa

9 Key Developments

10 Company Profiling
10.1 Insulet Corporation
10.1.1 Business Overview
10.1.2 Product/Service Offering
10.1.3 Financial Overview
10.1.4 SWOT Analysis
10.1.5 Key Activities
10.2 Medtrum Technologies Inc
10.3 Debiotic
10.4 Roche Holding AG
10.5 Spring Health Solution Ltd
10.6 Cellnovo Group SA
10.7 Johnson & Johnson
10.8 Abbott Diabetes Care
10.9 Medtronic Plc
10.10 CeQur SA
10.11 Veleritas
10.12 Tandem Diabetes Care
10.13 Animas Corporation